Blood:高血浆GDF-15水平与静脉血栓栓塞风险增加相关

2020-08-19 MedSci原创 MedSci原创

高GDF-15水平与静脉血栓栓塞风险增加强烈相关;孟德尔随机分析显示,GDF-15是静脉血栓栓塞的风险标志物,而不是致病风险因子。

中心点:

高GDF-15水平与静脉血栓栓塞风险增加强烈相关;

孟德尔随机分析显示,GDF-15是静脉血栓栓塞的风险标志物,而不是致病风险因子。

摘要:

生长分化因子15(GDF-15)是炎症和氧化应激的标志物,已成为动脉血管疾病的生物标志物。然而,GDF-15和静脉血栓栓塞(VTE)之间的关系仍不确定。

因此,Hansen等调查了血浆GDF-15水平与未来发生静脉血栓栓塞的风险之间的关系,并使用孟德尔随机化(MR)方法探索了其因果关系的可能性。

这是一项基于人群的嵌套病例对照研究,招募了416名静脉血栓栓塞患者和848名来自Tromsø 研究的年龄和性别匹配的对照。Logistic回归用于计算GDF-15四分位数间静脉血栓栓塞的优势比(OR)。

结果发现,VTE的OR值在GDF-15四分位数中增加(趋势P=0.002)。在年龄和性别调整的模型中,GDF15值位于最高四分位数(≥358pg/mL)的受试者与GDF15值位于最低四分位数(<200pg/mL)的受试者相比,发生VTE的OR为2.05(95%CI 1.3 7~3.08)。在进一步校正体重指数、吸烟、激素治疗、体力活动和C反应蛋白后,ORS基本上保持不变。在诱发/非诱发事件、深静脉血栓形成和肺栓塞方面也有类似的结果。与SNPs预测的一致,在MR中,GDF-15水平与VTE无关。

本研究结果表明,高GDF-15水平与VTE风险增加相关,但孟德尔随机分析提示这种联系不是因果关系。

原始出处:

Hansen Ellen-Sofie,Hindberg Kristian,Latysheva Nadezhda et al. Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism. Blood, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698136, encodeId=22de16981364a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 07 10:53:32 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956596, encodeId=73e79565961e, content=好用🧐, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cadd5411997, createdName=ms4000000902214885, createdTime=Tue Apr 13 14:53:28 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770100, encodeId=78411e70100df, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Tue Oct 20 11:53:32 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955504, encodeId=2ecc1955504f5, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Aug 04 05:53:32 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811121, encodeId=eb4a811121e3, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a85411660, createdName=曲流觞, createdTime=Wed Aug 19 18:13:19 CST 2020, time=2020-08-19, status=1, ipAttribution=)]
    2020-11-07 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698136, encodeId=22de16981364a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 07 10:53:32 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956596, encodeId=73e79565961e, content=好用🧐, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cadd5411997, createdName=ms4000000902214885, createdTime=Tue Apr 13 14:53:28 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770100, encodeId=78411e70100df, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Tue Oct 20 11:53:32 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955504, encodeId=2ecc1955504f5, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Aug 04 05:53:32 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811121, encodeId=eb4a811121e3, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a85411660, createdName=曲流觞, createdTime=Wed Aug 19 18:13:19 CST 2020, time=2020-08-19, status=1, ipAttribution=)]
    2021-04-13 ms4000000902214885

    好用🧐

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1698136, encodeId=22de16981364a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 07 10:53:32 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956596, encodeId=73e79565961e, content=好用🧐, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cadd5411997, createdName=ms4000000902214885, createdTime=Tue Apr 13 14:53:28 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770100, encodeId=78411e70100df, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Tue Oct 20 11:53:32 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955504, encodeId=2ecc1955504f5, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Aug 04 05:53:32 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811121, encodeId=eb4a811121e3, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a85411660, createdName=曲流觞, createdTime=Wed Aug 19 18:13:19 CST 2020, time=2020-08-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698136, encodeId=22de16981364a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 07 10:53:32 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956596, encodeId=73e79565961e, content=好用🧐, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cadd5411997, createdName=ms4000000902214885, createdTime=Tue Apr 13 14:53:28 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770100, encodeId=78411e70100df, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Tue Oct 20 11:53:32 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955504, encodeId=2ecc1955504f5, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Aug 04 05:53:32 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811121, encodeId=eb4a811121e3, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a85411660, createdName=曲流觞, createdTime=Wed Aug 19 18:13:19 CST 2020, time=2020-08-19, status=1, ipAttribution=)]
    2021-08-04 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698136, encodeId=22de16981364a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 07 10:53:32 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956596, encodeId=73e79565961e, content=好用🧐, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cadd5411997, createdName=ms4000000902214885, createdTime=Tue Apr 13 14:53:28 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770100, encodeId=78411e70100df, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Tue Oct 20 11:53:32 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955504, encodeId=2ecc1955504f5, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Aug 04 05:53:32 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811121, encodeId=eb4a811121e3, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5a85411660, createdName=曲流觞, createdTime=Wed Aug 19 18:13:19 CST 2020, time=2020-08-19, status=1, ipAttribution=)]
    2020-08-19 曲流觞

    1

    0

相关资讯

Brit J Heamatol:接受免疫调节剂治疗的多发性骨髓瘤患者静脉血栓栓塞的一级预防

低剂量阿哌沙班作为接受IMiD治疗的MM患者VTE一级预防策略是安全的,且耐受性良好。需要进一步的研究以验证低剂量阿哌沙班是否可作为接受IMiD治疗的MM患者抗血栓形成标准的一级预防策略。

Brit J Heamatol:静脉血栓栓塞门诊患者维生素K拮抗剂治疗期间大出血的预测

该研究所开发的风险评分可以识别出门诊病人中有明显出血风险的病人,特别是有大出血风险病人。

Blood:PAR4激活的结构基础及在VTE中的作用

PAR4激活需要在由TM3和TM7形成的束缚配体结合位点上的ECL3和Thr153的协调重排。与Pro310相比,ECL3中的PAR4 Leu310具有较低的受体反应性,并与VTE风险降低有关。

ATVB:COVID-19肺炎和社区获得性肺炎患者静脉血栓栓塞风险比较

该研究的结果表明COVID-19肺炎与高凝状态有关。但是,COVID-19肺炎患者的VTE发生率并未明显高于CAP患者。

所有住院患者均应评估静脉血栓栓塞风险!美国心脏协会声明

据报道,在美国,住院期间或住院后3个月内,发生的静脉血栓栓塞占所有静脉血栓栓塞的50%以上。

Circulation:发生急性冠脉综合征后的外周动脉疾病和静脉血栓栓塞风险及影响因素

急性冠状动脉综合征的患者有发生外周动脉疾病(PAD)和静脉血栓栓塞(VTE)的风险。PCSK9(前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型)抑制剂可降低脂蛋白(a)和低密度脂蛋白胆固醇(LDL-C